Triple-negative breast cancers (TNBCs) neither express estrogen receptor and progesterone receptor nor overexpress human epidermal growth factor receptor-2. Because of the special molecular features, triple-negative breast cancer is not either sensitive to endocrine therapy or targeted therapy of trastuzumab. There has not been standard treatment regimen for triple-negative breast cancer yet and chemotherapy has still been the chief therapy currently. However, with the great progress of oncology and molecular biology, the understanding of the natural history, pathophysiology and molecular features of this disease has been greatly improved, and a growing number of novel and effective therapies and discoveries of new biological targets for this phenotype of breast cancers have been reported, which provide new insights into therapeutic strategies for the women suffering from it.
This is a preview of subscription content, log in to check access.
Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer, 2007, 109: 1721–1728.
Yamamoto Y, Ibusuki M, Kawasoe T, et al. Basal cell-like signature is an independent prognostic factor in triple-negative breast cancer. J Clin Oncol, 2008, 26: 22184.
Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol, 2008, 26: 1275–1281.
Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res, 2005, 11: 5678–5685.
Nunes JS, Tsunoda AT, Viana LS, et al. Analysis of response to neoadjuvant chemotherapy (NCT) with doxorubicin plus cyclophosphamide followed by paclitaxel (AC-T) in triple negative locally advanced breast cancer (LABC) in Brazil. J Clin Oncol, 2008, 26: 11551.
Chang HR, Glaspy J, Allison MA, et al. Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment. Cancer, 2010, 116: 4227–4237.
Banerjee S, Reis-Filho JS, Ashley S, et al. Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J Clin Pathol, 2006, 59: 729–735.
Steponaviciene L, Lachej-Mikeroviene N, Smailyte G, et al. Triple negative breast cancer: adjuvant chemotherapy effect on survival. Adv Med Sci, 2011, 56: 285–290.
Königsberg R, Pfeiler G, Kurzawa R, et al. Prognostic assessment and adjuvant treatment strategies within early-stage, sporadic triple negative breast cancer patients. Cancer Invest, 2011, 29: 180–186.
Kashiwagi S, Yashiro M, Takashima T, et al. Advantages of adjuvant chemo -therapy for patients with triple-negative breast cancer at Stage II: usefulness of prognostic markers E-cadherin and Ki67. Breast Cancer Res, 2011, 13: R122.
Gluz O, Nitz UA, Harbeck N, et al. Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial. Ann Oncol, 2008, 19: 861–870.
Chia JW, Ang P, See H, et al. Triple-negative metastatic/recurrent breast cancer: Treatment with paclitaxel/carboplatin combination Chemotherapy. J Clin Oncol, 2007, 25: 1086.
Zaniboni A, Meriggi F, Rizzi A, et al. Navelbine (N), leucovorin (L), and fluorouracil (5-FU) (FLN) for triple-negative metastatic breast cancer (TNBC). J Clin Oncol 2008, 26: 1127.
Maisano R, Zavettieri M, Azzarello D, et al. Carboplatin and gemcitabine combination in metastatic triple-negative anthracycline- and taxane-pretreated breast cancer patients: a phase II study. J Chemother, 2011, 23: 40–43.
Ozkan M, Berk V, Kaplan MA, et al. Gemcitabine and cisplatin combination chemotherapy in triple negative metastatic breast cancer previously treated with a taxane/anthracycline chemotherapy; multicenter experience. Neoplasma. 2012, 59: 38–42.
Chen Y, Wang ZY, Yao Y, et al. The effect and side effects of Gem-citabine plus Vinorelbine in patients with triple-negative metastatic breast cancer. Chinese-German J Clin Oncol, 2009, 8: 557–560.
Haffty BG, Yang Q, Reiss M, et al. Locoregional and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol, 2006, 24: 5652–5657.
Wang J, Shi M, Ling R, et al. Adjuvant chemotherapy and radiotherapy in triple-negative breast carcinoma: a prospective randomized controlled multi-center trial. Radiother Oncol, 2011, 100: 200–204.
Comen E, Davids M, Kirchhoff T, et al. Relative contributions of BRCA1 and BRCA2 mutations to “triple-negative” breast cancer in Ashkenazi Women. Breast Cancer Res Treat, 2011, 129: 185–190.
Lee E, McKean-Cowdin R, Ma H, et al. Characteritics of triple-negative breast cancer in patients with a BRCA1 mutation:results from a population-based study of young women. J Clin Oncol, 2011, 29: 4373–4380.
Kennedy RD, Quinn JE, Mullan PB, et al. The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst, 2004, 96: 1659–1668.
El Guerrab A, Zegrour R, Nemlin CC, et al. Differential impact of EGFR-targeted therapies on hypoxia responses: implications for treatment sensitivity in triple-negative metastatic breast cancer. PLoS One, 2011, 6: e25080.
Deng XS, Wang S, Deng A, et al. Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers. Cell Cycle, 2012, 11: 367–376.
Moon HG, Hwang KT, Kim JA, et al. NFIB is a potential target for estrogen receptor-negative breast cancers. Mol Oncol, 2011, 5: 538–544.
Tryfonopoulos D, Walsh S, Collins DM, et al. Src: a potential target for the treatment of triple-negative breast cancer. Ann Oncol, 2011, 22: 2234–2240.
Föst C, Duwe F, Hellriegel M, et al. Targeted chemotherapy for triplenegative breast cancers via LHRH receptor. Oncol Rep, 2011, 25: 1481–1487.
King TD, Suto MJ, Li Y. The Wnt/β-catenin signaling pathway: a potential therapeutic target in the treatment of triple negative breast cancer. J Cell Biochem, 2012, 113: 13–18.
O’shaughnessy J, Osborne C, Pippen JE, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med, 2011, 364: 205–214.
Zeng Q, Yang Z, Gao YJ, et al. Treating triple-negative breast cancer by a combination of rapamycin and cyclophosphamide: an in vivo biolumine -scence imaging study. Eur J Cancer, 2010, 46: 1132–1143.
Rainville C, Khan Y, Tisman G. Triple negative breast cancer patients presenting with low serum vitamin D levels: a case series. Cases J, 2009, 2: 8390.
Harputluoglu H, Dizdar O, Karaahmet F, et al. Vitamin D intake may be effective in the management of triple-negative breast cancer. J BUON, 2011, 16: 569.
About this article
Cite this article
Shi, X., Wang, L. Treatment for triple-negative breast cancer. Chin. -Ger. J. Clin. Oncol. 11, 539–543 (2012). https://doi.org/10.1007/s10330-012-1023-8
- breast neoplasms